Warm Autoimmune Hemolytic Anemia Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
The main objective of the study is to evaluate the safety and efficacy of ALXN1830 compared to placebo in adult participants with warm autoimmune hemolytic anemia (WAIHA).
This study will consist of a 4-week Screening period, 13-week Primary Treatment period, and optional Extended Treatment period (up to 2 years). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05786573 -
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
|
Phase 3 | |
| Withdrawn |
NCT03965624 -
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
|
Phase 2 | |
| Recruiting |
NCT05922839 -
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
|
Phase 2 | |
| Completed |
NCT01181154 -
Rituximab in Auto-Immune Hemolytic Anemia
|
Phase 3 | |
| Recruiting |
NCT05925023 -
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
|
Phase 2 | |
| Recruiting |
NCT05757570 -
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias
|
Phase 1/Phase 2 | |
| Terminated |
NCT03075878 -
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04956276 -
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
|
Phase 2 | |
| Completed |
NCT03226678 -
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
|
Phase 2 | |
| Recruiting |
NCT04119050 -
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
|
Phase 2/Phase 3 | |
| Terminated |
NCT04253236 -
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
|
Phase 2 | |
| Temporarily not available |
NCT05221619 -
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
|